The results of the use of the natural complex Resverazin® in treatment of vascular retinal disorders | Ukrainian Medical Journal

Babenko T.F.,Dorichevskaya R.Y.,Fedirko P.A.

Main
Publications
The results of the use of the natural complex Resverazin® in treatment of vascular retinal disorders

The results of the use of the natural complex Resverazin® in treatment of vascular retinal disorders

June 22, 2018

1154

Specialities :

Resume

In an open-label study, we studied the efficacy of the natural antioxidant complex Resverazin®, containing resveratrol 150 mg, red wine extract 100 mg and grape seed extract 50 mg, in the ophthalmic practice. A group of 20 volunteers selected based on the criterion of marked retinal angiopathy was administered 1 capsule of the complex Resverazin® twice daily for 2 months. A pre- and post-study standard ocular examination was performed, including vizometry, biomicroscopy, capillaroscopy of the bulbar conjunctiva, tonometry, refractometry, ophthalmoscopy, optical coherence tomography, fundus imaging with a fundus camera in the standard settings. The study results demonstrated a statistically significant increase in the visual acuity, improved microcirculation in the bulbar conjunctiva, and increased retinal artery diameter after Resverazin® administration, without any adverse effects. The natural complex can be recommended for use in ophthalmic practice in treatment regimens intended for vascular retinal disorders of various origins.

Published: 27.06.2018

References:

Pasechnikova N.V., Korol A.R. (2010) Klinicheskaya klassifikatsiya i taktika lecheniya patsientov s vozrastnoy makulyarnoy degeneratsiey. zhurn., (2): 38–41.
Razumovskaya A.M., Razumovskiy M.I., Korovyanskiy Yu.A. (2017) Sravnitelnaya effektivnost primeneniya metiletilpiridinola putem endonazalnogo elektroforeza i parabulbarnyih in’ektsiy pri horioretinalnoy distrofii. Oftalmologiya, 14(3): 268–273.
Savko V.V., Savko V.V. (ml.) (2016) K voprosu o korrektsii narusheniya gemodinamiki glaza pri ostroy ishemicheskoy neyropatii zritelnogo nerva Oftalmol. zhurn., 2: 23–27.
Surovaya E.I., Boychuk I.M. (2016) Sostoyanie zritelnyih funktsiy u patsientov s miopiey do i posle medikamentoznoy korrektsii antioksidantnoy sistemyi. Oftalmol. zhurn., 1: 8–11.
Shved A.M. (2006) Patohenetychne obgruntuvannia kombinovanoho zastosuvannia inhibitoriv anhiotenzynperetvoriuvalnoho fermentu ta systemnoi enzymoterapii pry diabetychnii retynopatii. Avtoref. dys. … kand. med. nauk, NMAPO imeni P.L. Shupyka, Kyiv, 20 s.Abu-Amero Kh.K., Kondkar A.A., Chalam K.V. (2016) Resveratrol and ophthalmic diseases. Nutrients, 8(4): 200.
Babenko T.F., Fedirko P.A., Dorichevska R.Y. et al. (2016) The risk of macular degeneration development in persons antenatally irradiated as a result of Chornobyl NPP accident. Probl. rad. med. radiobiol., 21: 172–177.
Cavallini G., Straniero S., Donati A., Bergamini E. (2016) Resveratrol requires red wine polyphenols for optimum antioxidant activity. J. Nutr. Health Aging, 20(5): 540–545.
Fedirko P.A., Babenko T.F., Dorichevska R.Y., Garkava N.A. (2015) Retinal vascular pathology risk development in the irradiated at different ages as a result of Chernobyl NPP accident. Probl. Radiac. Med. Radiobiol., 20: 467–573.
Friedman E. (1997) A Hemodynamic model of the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol., 124(5): 677–682.
Goldenberg D., Shahar J., Loewenstein A., Goldstein M. (2013) Diameters of retinal blood vessels in a healthy cohort as measured by spectral domain optical coherence tomography. Retina. 33(9): 1888–1894.
Kanavi M.R., Darjatmoko S., Wang S. et al. (2014) The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization. Molecules, 19(11): 17578–17603.
Ko J-H., Sethi G., Um J-Y. et al. (2017) The role of resveratrol in cancer therapy. Int. J. Mol. Sci., 18: 2589.
Kubota S., Kurihara T., Mochimaru H. (2009) Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor κB activation. Investig. Ophthalmol. Vis. Sci., 50: 3512–3519.
Kumar B.J., Joghee N.M. (2013) Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int. Res. J. Pharm., 4(8): 246–249.
Lippi G., Franchini M., Favaloro E.J., Targher G. (2010) Moderate red wine consumption and cardiovascular disease risk: Beyond the «french paradox». Semin. Thromb. Hemost., 36: 59–70.
López M., Cos F.X., Álvarez-Guisasola F., Fusterd E. (2017) Prevalence of diabetic retinopathy and its relationship with glomerular filtration rate and other risk factors in patients with type 2 diabetes mellitus in Spain. DM2 HOPE study. J. Clin. Transl. Endocrinol., 9(9): 61–65.
Luna C., Li G., Liton P.B. et al. (2009) Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem. Toxicol., 47: 198–204.
Mokni M., Hamlaoui S., Karkouch I. et al. (2013) Resveratrol provides cardioprotection after ischemia/reperfusion injury via modulation of antioxidant enzyme activities. Iranian J. Pharm. Res., 12(4): 867–875.
Nagineni Ch.N., Raju R., Nagineni K.K. et al. (2014) Resveratrol suppresses expression of VEGF by human retinal pigment epithelial cells: potential nutraceutical for age-related macular degeneration. Aging Dis., 5(2): 88–100.
Novelle M.G., Wahl D., Dieguez C. et al. (2015) Resveratrol supplementation: Where are we now and where should we go? Ageing Res. Rev., 5: 1–15.
Shrotriya S., Tyagi A., Deep G. et al. (2015) Grape seed extract and resveratrol prevent 4-nitroquinoline 1-oxide induced oral tumorigenesis in mice by modulating AMPK activation and associated biological responses. Mol. Carcinog., 54(4): 291–300.
Singh N., Agrawal M., Dore S. (2013) Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem. Neurosci., 4: 1151−1162.
Smoliga J.M., Blanchard O. (2014) Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules, 19(11): 17154–17172.
Wen D., Huang Xi., Zhang M. et al. (2013) Resveratrol attenuates diabetic nephropathy via modulating angiogenesis, PLoS One, 8(12): e82336.
Wong W.L., Su X., Li X. et al. (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health, 2(2): e106–e116.
Zheng Yi, Yaohua L., Ge J. et al. (2010) Resveratrol protects human lens epithelial cells against H2O2 — induced oxidative stress by increasing catalase, SOD-1, and HO-1 expression. Vis., 16: 1467–1474.